Gabriel-Stefan Nadj

Dr. Gabriel-Stefan Nadj


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2026 in Molecules
Verified
Journal Article
Open access
PDF file
DSDragan Stajić
Dragan Stajić
MBMirjana A. Bogavac
Mirjana A. Bogavac
MSMarko Sinisa Stojic
Marko Sinisa Stojic
GNGabriel-Stefan Nadj
Gabriel-Stefan Nadj
MIMarko Ilinčić
Marko Ilinčić
Jovana MiskovicJovana Miskovic
Jovana Miskovic
Pregnancy involves profound metabolic, hormonal, and immunological adaptations essential for fetal development; however, disturbances may lead to complications such as preeclampsia (PE), pre-gestational diabetes, and gestational diabetes mellitus (GDM). These conditions are closely linked to oxidative stress, inflammation, endothelial dysfunction, impaired placentation, and metabolic dysregulation. Consequently, dietary strategies capable of modulating these pathways are of increasing interest. Edible and medicinal mushrooms are widely studied as functional food due to the content of bioactive compounds with antioxidant, anti-inflammatory, immunomodulatory, and metabolic regulatory effects. This review summarizes the nutritional composition of mushrooms and highlights key bioactive constituents with antioxidant and metabolic regulatory properties. Among them, ergothioneine has emerged as a key molecule due to its potent redox-buffering capacity and its potential involvement in the activation of the Nrf2 signaling pathway, a master regulator of cellular antioxidant defense. Through modulation of Nrf2-dependent gene expression, mushroom-derived compounds may contribute to improved cellular resilience against oxidative damage relevant to PE and GDM pathophysiology. Mushroom consumption has additionally been associated with improved glycemic control and enhanced antioxidant defenses in experimental and limited clinical studies, although evidence regarding the prevention or management of hypertensive and metabolic pregnancy complications remains insufficient. Although preclinical findings are promising, clinical evidence remains limited. Further well-designed prospective studies and randomized controlled trials are required to determine efficacy, safety, optimal intake, and active compounds responsible for these effects. Nevertheless, current evidence supports the biological plausibility that edible and medicinal mushrooms are promising dietary modulators of the ergothioneine–Nrf2 axis with potential relevance for maternal–fetal health.

5 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
DSDragan Stajić
Dragan Stajić
MBMirjana A. Bogavac
Mirjana A. Bogavac
MSMarko Sinisa Stojic
Marko Sinisa Stojic
GNGabriel-Stefan Nadj
Gabriel-Stefan Nadj
MIMarko Ilinčić
Marko Ilinčić
Jovana MiskovicJovana Miskovic
Jovana Miskovic
Pregnancy involves profound metabolic, hormonal, and immunological adaptations essential for fetal development; however, disturbances may lead to complications such as preeclampsia (PE), pre-gestational diabetes, and gestational diabetes mellitus (GDM). These conditions are closely linked to oxidative stress, inflammation, endothelial dysfunction, impaired placentation, and metabolic dysregulation. Consequently, dietary strategies capable of modulating these pathways are of increasing interest. Edible and medicinal mushrooms have emerged as functional foods rich in bioactive compounds with antioxidant, anti-inflammatory, immunomodulatory, and metabolic regulatory effects. This review summarizes the nutritional composition of mushrooms and highlights key bioactive constituents, such as ergothioneine, which may influence redox balance, immune responses, glucose metabolism, endothelial function, and placental development. Experimental evidence suggests that these compounds modulate pathways involved in PE and GDM pathogenesis. Mushroom consumption has additionally been associated with improved glycemic control, enhanced antioxidant defenses, and reduced risk of hypertensive and metabolic pregnancy complications. Although preclinical findings are promising, clinical evidence remains limited. Further well-designed prospective studies and randomized controlled trials are required to determine efficacy, safety, optimal intake, and active compounds responsible for these effects. Nevertheless, current evidence supports edible and medicinal mushrooms as potential dietary modulators of key mechanisms involved in PE and GDM, with relevance for improving maternal-fetal health outcomes.